Despite significant advances in pig-to-primate organ xenotransplantation, long-term graft survival is currently limited by the development of a thrombotic microangiopathy and platelet sequestration in the grafted organ and/or a consumptive coagulopathy in the recipient. The present proposal tests homogeneous heparin sulfates (HSs) synthesized using computational modeling and enzymatic/chemical tools as outlined in Projects I (PL-I. Dr. Balagurunathan) and II (Pl-ll. Dr. Desai). We hypothesize that chemically-synthesized HSs designed to preferentially inhibit Factor Xa (FXa) and/or thrombin will ameliorate the thrombotic microangiopathy and/or consumptive coagulopathy seen in the context of pig-to-primate xenografts by inhibiting thrombin formation and platelet activation. In addition, HSs optimized to bind chemokines (from Project III) may act as chemokine decoy factors to prevent cell sequestration synergistically with anticoagulation. These HSs will be evaluated in the context of various xenotransplantation models using cells and organs from pigs genetically modified to protect against antibody/complement-mediated, inflammatory, and coagulation rejection mechanisms. These HS-based therapies will be tested by. - (i) in vitro assays to determine the best HS candidate drugs for further studies, (ii) ex vivo pig lung hemoperfusion using human blood, (iii) pig artery Tx in baboons, and (iv) pig kidney Tx in baboons. Model (ii) constitutes a short-duration model (with graft function measured in hours) allowing rapid screening of the HSs being tested, whereas models (iii) and (iv) constitute longer-duration models (days or weeks). Furthermore, the effect of the HS will be monitored (iii) in a low-antigen load model without immunosuppressive therapy, or (iv) in a high-antigen load model in which graft recipients will receive immunosuppressive therapy aimed at inhibiting the adaptive T cell response. The prime aim of the study is to identify one (or more) HS that is more specific and more efficient at inhibiting the development of thrombotic microangiopathy and consumptive coagulopathy than is the current clinically-used heparin, and that, furthermore, is not associated with the side-effects of heparin, e.g., bleeding, that limit the dosage that can be administered.
The second aim i s to investigate the synergy between the HS identified as being optimal with the genetic manipulations in the organ-source pig, e.g., expression of human thrombomodulin directed towards inhibiting thrombotic microangiopathy and consumptive coagulopathy.
The transplantation of organs from genetically-engineered pigs would provide an alternative source to human organs for clinical transplantation, but is currently complicated by coagulation disturbances that can be fatal. The administration of specific synthetic heparan sulfates that will be designed and investigated in this proposal are likely to prevent these coagulation disturbances, thus enabling xenotransplantation to advance to clinical trials.
|Brown, Aaron J; Sepuru, Krishna Mohan; Sawant, Kirti V et al. (2017) Platelet-Derived Chemokine CXCL7 Dimer Preferentially Exists in the Glycosaminoglycan-Bound Form: Implications for Neutrophil-Platelet Crosstalk. Front Immunol 8:1248|
|Zhang, Haohai; Chan, Leo Li-Ying; Rice, William et al. (2017) Novel high-throughput cell-based hybridoma screening methodology using the Celigo Image Cytometer. J Immunol Methods 447:23-30|
|Iwase, Hayato; Liu, Hong; Li, Tao et al. (2017) Therapeutic regulation of systemic inflammation in xenograft recipients. Xenotransplantation 24:|
|Jiang, Z Gordon; Sandhu, Bynvant; Feldbrügge, Linda et al. (2017) Serum Activity of Macrophage-Derived Adenosine Deaminase 2 Is Associated With Liver Fibrosis in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol :|
|Brown, Aaron J; Sepuru, Krishna Mohan; Rajarathnam, Krishna (2017) Structural Basis of Native CXCL7 Monomer Binding to CXCR2 Receptor N-Domain and Glycosaminoglycan Heparin. Int J Mol Sci 18:|
|Zheng, Shuo; Kummarapurugu, Apparao B; Afosah, Daniel K et al. (2017) 2-O, 3-O Desulfated Heparin Blocks High Mobility Group Box 1 Release by Inhibition of p300 Acetyltransferase Activity. Am J Respir Cell Mol Biol 56:90-98|
|Longhi, Maria Serena; Vuerich, Marta; Kalbasi, Alireza et al. (2017) Bilirubin suppresses Th17 immunity in colitis by upregulating CD39. JCI Insight 2:|
|Iwase, Hayato; Hara, Hidetaka; Ezzelarab, Mohamed et al. (2017) Immunological and physiological observations in baboons with life-supporting genetically engineered pig kidney grafts. Xenotransplantation 24:|
|Bi, Yiling; Might, Matthew; Vankayalapati, Hariprasad et al. (2017) Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-?-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease. Bioorg Med Chem Lett 27:2962-2966|
|Iwase, Hayato; Liu, Hong; Schmelzer, Eva et al. (2017) Transplantation of hepatocytes from genetically engineered pigs into baboons. Xenotransplantation 24:|
Showing the most recent 10 out of 123 publications